Background: PDE6, the rod photoreceptor phosphodiesterase, is the key effector enzyme in phototransduction. Results: EM reconstructions of PDE6 complexed with various probes are presented. Conclusion: Fitting of x-ray structures yielded an atomic model of the catalytic subunits, and the locations of other structural features are indicated. Significance: These data offer the most complete view to date of the PDE6 holoenzyme.
Members of the type I family of cyclic nucleotide phosphodiesterases, comprising PDE1-PDE11 3 (1, 2) , operate in a sinksource relationship with cyclase enzymes to control the levels of the key second messengers cGMP and cAMP. PDEs are targets of several widely used drugs and remain a major target for drug development. The family is defined by a conserved catalytic domain, outside of which family members display diverse domain structures and regulatory mechanisms. Five mammalian subfamilies contain non-catalytic cyclic nucleotide binding regulatory GAF domains: PDE2, PDE5, PDE6, PDE10, and PDE11. The cGMP-specific PDE6 isozymes of vertebrate rod and cone photoreceptors are unique in containing two tightly bound inhibitory ␥ subunits (3, 4) . PDE6 is a heterotetramer containing two ␥ subunits as well as the homologous ␣ and ␤ subunits in rods (PDE6␣␤␥␥) or the related ␣Ј subunits in cones (PDE6␣Ј␣Ј␥␥). Each ␣ or ␤ subunit contains two N-terminal GAF domains (GAFa and GAFb) and a C-terminal catalytic domain. High resolution structures are available for isolated domains or fragments of PDE isozymes, including PDE6 and PDE5 (5) (6) (7) (8) (9) (10) , and a crystal structure of nearly full-length PDE2A (11) includes both GAF and catalytic domains. Although several low resolution structures of PDE6 based on electron microscopy in negative stain have been published (12) (13) (14) , the structural relationships between the GAF and catalytic domains is unknown. In addition, the location and conformation of the PDE6␥ subunits are largely unknown.
PDE6␥ binds to the catalytic domains of ␣/␤ subunits, where its C-terminal residues block the active site (10, (15) (16) (17) (18) (19) (20) 63) . In the course of the phototransduction cascade, the G protein transducin ␣ subunit (G ␣t ) sequesters the PDE6␥ C terminus, relieving the inhibition (5, 17, 21) . PDE6␥ binding is also strongly coupled to cGMP binding at noncatalytic sites in the GAFa domain (22) (23) (24) (25) (26) . Such interdomain regulation by the 9.7-kDa PDE6␥ polypeptide requires either proximity of GAFa and catalytic domains in the quaternary structure, a highly extended conformation for PDE6␥, or long range allosteric control. Cross-linking studies (20, 27, 64 ) support a PDE6␥ extended conformation, with contact made between PDE6␥ and all three domains of the catalytic subunits, but direct structural evidence is lacking.
We have used cryo-electron microscopy (cryo-EM) to determine the overall structure of PDE6. The higher resolution map revealed previously unseen features of the PDE6 structure and permitted definitive orientation of the GAF domains. Visualization of antibody Fab fragments bound to the C or N terminus of PDE6␥ was used to investigate the positioning of the inhibitory subunit in the holoenzyme, and imaging of PDE6⅐PrBP/␦ complexes revealed the locations of the PrBP/␦ binding sites and the C-terminal prenylations of PDE6␣/␤. Finally, we char-acterized a dramatic structural rearrangement of the catalytic subunits in the absence of PDE6␥.
EXPERIMENTAL PROCEDURES
Extraction and Purification of PDE6 -Extraction and purification of PDE6 from bovine rod outer segment (ROS) membranes were as described (28) . Briefly, ROS were prepared from 300 frozen dark-adapted bovine retinas (InVision Bio-Resources, Seattle, WA) and purified by sucrose gradient fractionation. For PDE6 purification, several ROS preparations were pooled, bleached in room light, and sequentially washed with moderate salt buffer (10 mM MOPS, pH 7.4, 30 mM NaCl, 60 mM KCl, 2 mM MgCl 2 ) and low salt buffer (5 mM Tris-HCl, pH 7.2, 0.5 mM MgCl 2 ) to produce a highly-enriched PDE6 extract. PDE6 was purified with hydroxyapatite chromatography (Bio-Rad) using a step gradient elution with phosphate buffers to remove HSP90 contamination (28) followed by HPLC gel filtration using a Bio-Sil SEC 250 -5 column (Bio-Rad). Purified PDE6 was concentrated with a Centricon-50 (Millipore) and stored in 20 mM sodium phosphate, pH 7.5, 150 mM NaCl, 2 mM MgCl 2 , 2 mM DTT, and 40% glycerol at Ϫ20°C.
PDE6 used for complex formation with PrBP/␦ was purified from 800 bovine retinas as previously described (3) . Briefly, ROS membranes were purified by sucrose gradient centrifugation and washed 5 times with isotonic buffer (10 mM Tris-HCl, pH 7.4, 0.1 M NaCl, 1 mM EDTA, 0.1 mM DTT) followed by hypotonic buffer (10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.1 mM DTT). Hypotonic supernatants were concentrated using Vivaspin 15 concentrators (Sartorius Stedim, Goettingen Germany). PDE6 was purified by gel filtration chromatography (SD200, Amersham Biosciences/GE Healthcare) in 100 mM NaCl, 10 mM Tris, pH 7.4, 1 mM DTT. Typical yields were ϳ1.5 mg of ϳ99% pure PDE6.
Purification of Fab Fragments-ROS-1 hybriboma cells (29) were kindly provided by Dr. Richard L. Hurwitz (Baylor College of Medicine, Houston TX), and ascites fluid containing ROS-1 monoclonal antibody (mAb) was produced by Maine Biotechnology Services, Inc. (Portland, ME). ROS-1 mAb was purified with ImmunoPure Immobilized protein L (Pierce) following the manufacturer's instructions. The pure fractions of ROS-1 mAb were pooled and dialyzed against digestion buffer (20 mM Tris, pH 7.6, 50 mM NaCl, 1.25 mM EDTA, 20 mM cysteine). Purified ROS-1 mAb was concentrated and digested with papain (Sigma) at a ratio of 10 g of papain to 1 mg of mAb in digestion buffer at 37°C for at least 4 h. After confirming by SDS-PAGE that the digestion was complete, the protease was inactivated by incubating with 75 mM iodoacetamide at room temperature for 30 min. The Fab fragment was purified using ImmunoPure Immobilized protein L. For human influenza hemagglutinin (HA) Fab, HA mAb clone 16B12 (Covance) was digested with papain as above. The Fab fragment was purified with a BioSuite weak-cation exchange CM column (Waters) in a gradient of 30 mM MES, pH 6.3, versus 30 mM MES, pH 6.3, with 1 M sodium acetate and a flow rate of 1 ml/min. The purity of the Fab fragments was confirmed by SDS-PAGE and Coomassie staining.
Expression and Purification of Recombinant PDE6␥-Synthetic bovine PDE6␥ subunit cDNA (30) was subcloned into to the pET14b vector (Novagen), thereby adding an N-terminal His 6 tag. PDE␥ constructs containing the N-terminal His 6 tag as well as the HA epitope (YPYDVPDYA) at either the N or C terminus, separated from the PDE6␥ sequence by the linker SGGGGS, were cloned by PCR. Recombinant PDE6␥ was expressed in BL21(DE3)pLysS Escherichia coli (Novagen). PDE6␥ in inclusion bodies was solubilized with 6 M guanidinium chloride and purified with a Ni-NTA Fastflow (Qiagen) column under denaturing conditions following the manufacturer's protocol followed by a HPLC C 4 reverse-phase column (VyDac, Discovery Sciences) as described (31) . Purified recombinant PDE6␥ was lyophilized by SpeedVac to remove acetonitrile and trifluoroacetic acid and stored at Ϫ80°C.
Preparation of PDE6⅐ROS-1-Fab Complexes-Purified ROS-1 Fab was mixed with purified PDE6 at a Fab:PDE6 molar ratio of 2:1 and incubated at 4°C for 30 min. The complex was purified by gel filtration (Bio-Sil SEC-250-5, Bio-Rad) in 20 mM sodium phosphate, pH 7.5, 150 mM NaCl. The pure complexes were examined by SDS-PAGE, concentrated, filtered through a 0.2-m spin-X cellulose acetate filter (Costar), and used directly for cryo-EM.
Limited Proteolysis of PDE6 and Preparation of PDE6⅐HA-Fab Complexes-Purified PDE6 was treated with trypsin in PDE6 assay buffer (10 mM MOPS, pH 8.0, 150 mM NaCl, 1 mM MgCl 2 , and 0.1 mM EDTA) for 8 min at room temperature at a PDE6:trypsin molar ratio of 100:1. Soybean trypsin inhibitor (Sigma) was added at a 10-fold molar excess over trypsin to terminate the proteolysis. Trypsinized PDE6 (tPDE6) was purified by gel filtration (Bio-Sil SEC-250-5, Bio-Rad) in 20 mM sodium phosphate, pH 7.5, 100 mM NaCl, 2 mM MgCl 2 . The activity of tPDE6 was monitored with a pH assay (28, 32) .
To prepare PDE6⅐HA-Fab complexes, purified tPDE6 was mixed with HA-Fab and N or C terminally HA-tagged PDE6␥ at a molar ratio of 1:2.5:2.5 and incubated at 4°C for 4 h. Complexes were purified by gel filtration as above. All recombinant PDE6␥ proteins were tested for inhibitory function, indicating catalytic domain binding, as well as for mediation of cGMP binding to the GAF domain.
Expression and Purification of Recombinant Human PrBP/␦-PrBP/␦ cDNA was amplified by PCR from a human retina cDNA library and cloned into a pET151/D-TOPO vector (Invitrogen). The construct was expressed in BL21 Codonϩ E. coli cells (Stratagene) in ZY autoinduction media for 6 h at 37°C and then overnight at 19°C. Cells were harvested by centrifugation, resuspended, and lysed with 10 mg/ml lysozyme in lysis buffer (20 mM imidazole, 700 mM NaCl, 50 mM Tris pH 7.4, 1 mM DTT) and protease inhibitors (PMSF, aprotinin, leupeptin, pepstatin) for 1 h at 4°C followed by sonication. The lysate was clarified by centrifugation, and soluble PrBP/␦ protein was bound to a Ni 2ϩ -Sepharose column (Amersham Biosciences/GE Healthcare), washed with 10 column volumes of lysis buffer, and eluted with 300 mM imidazole in 700 mM NaCl, 50 mM Tris, pH 7.4, and 1 mM DTT. Fractions were assayed by SDS-PAGE, pooled, and dialyzed against 2 liters of 20 mM NaCl, 25 mM Tris, pH 7.4, and 1 mM DTT. PrBP/␦ was purified to homogeneity by anion exchange (HiTrap Q FF, GE Healthcare Life Sciences) with a 20 -1000 mM NaCl gradient in 25 mM Tris, pH 7.4, 1 mM DTT, and gel filtration (SD200, Amersham Bio-sciences/GE Healthcare) in 100 mM NaCl, 10 mM Tris, pH 7.4, 1 mM DTT.
Preparation of PDE6⅐PrBP/␦ Complexes-A 3-fold molar excess of pure recombinant PrBP/␦ was added to purified PDE6 and incubated at 4°C for a minimum of 4 h. The complex was purified by gel filtration chromatography (SD200, Amersham Biosciences/GE Healthcare) in 10 mM Tris, pH 7.4, 100 mM NaCl, 1 mM DTT. Fractions were analyzed by SDS-PAGE, and pure fractions were combined and concentrated. The complex was stored in 40% glycerol at Ϫ20°C.
PDE6⅐PrBP/␦ complexes were dialyzed against gel filtration buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 2 mM MgCl 2 ) at 4°C overnight to remove glycerol, concentrated with a Centricon-50, and purified by gel filtration (Bio-Rad, Bio-Sil SEC 250 -5) in gel filtration buffer. The purity of the fractions was confirmed by SDS-PAGE, and the peak fractions were pooled and diluted to 0.2-0.3 mg/ml with gel filtration buffer. In some experiments, complexes were dialyzed, concentrated, filtered through a 0.2-m cellulose acetate filter, and used directly for cryo-EM.
cGMP Binding Assay-To determine whether the HA-tagged PDE6␥ could regulate cGMP binding to the non-catalytic sites in the GAF domains of PDE6␣␤, cGMP binding in the noncatalytic sites was measured using a modification of the assay described by Cote (33) . tPDE6 in 10 mM MOPS, pH 8.0, 150 mM NaCl, 1 mM MgCl 2 , and 0.1 mM EDTA was incubated at 30°C for 2 h to deplete the endogenous cGMP and purified by gel filtration. The cGMP-free tPDE6 was reconstituted with HAtagged PDE6␥ as described above. The reconstituted PDE6 was incubated in 20 mM sodium phosphate, pH 7.5, 150 mM NaCl with or without additional trypsin for 90 s at room temperature. Soybean trypsin inhibitor was added at a 10-fold molar excess over trypsin in all samples, then the reaction buffer was added to give final concentrations of 20 mM HEPES, pH 7.5, 30 mM NaCl, 60 mM KCl, 1 mM phosphate, protease inhibitor mixture (2 g/ml aprotinin, 2 g/ml chymostatin, 0.5 g/ml leupeptin, 0.7 g/ml pepstatin A, 30 g/ml trypsin inhibitor, 1.56 mg/ml benzamide, 0.1 M E64, and 0.16 mM Pefabloc), 0.5 mg/ml ovalbumin, 1 mM zaprinast, and 0.1 mM EDTA. The samples were incubated with 1.5 M cGMP solution containing [ 3 H]cGMP (Amersham Biosciences) at room temperature for 3 or 20 min. 60 l of the reaction mixture was directly filtered through pre-wet nitrocellulose membranes (Type HA, 0.45 m, Millipore) in a vacuum manifold (Hoefer Scientific Instruments) and quickly rinsed 3 times with 3 ml of ice-cold buffered ammonium sulfate (10 mM Tris, pH 7.5, 95% saturated ammonium sulfate). [ 3 H]cGMP retained on the membranes was quantified by scintillation counting.
Electron Microscopy-For cryo-electron microscopy, protein solutions at 0.2-0.5 mg/ml were applied to glow-discharged Quantifoil grids (Quantifoil Micro Tools) with 2.0-m holes. A Vitrobot Mark III (FEI) set to 22°C and 95% humidity was used for freezing. Images in ice were obtained using a JEOL2010F microscope equipped with a Gatan liquid nitrogen cryoholder and 4k ϫ 4k CCD camera. CCD images were acquired using a dose of 15-18 e/Å 2 and magnification of 60,000 ϫ (1.81 Å/pixel). For negative stains, specimens were applied to carbon-coated copper grids and stained with 2% uranyl acetate.
PDE6 and tPDE6 samples in negative stain were imaged for single-particle data collection with a JEOL 1200EX microscope at 100 KV at a dose of 15-18 e/Å 2 and a magnification of 60,000ϫ. For tomogram data collection tPDE6 samples were imaged with a JEM2100 microscope with SerialEM software (34) at 200 KV. Single-axis tilt series of negatively stained grids were collected from Ϫ60 to ϩ60°in 2°increments with an average dose of 25 e/Å 2 per micrograph and magnification of 60,000ϫ (1.82 Å/pixel).
Image processing was performed using EMAN (35) . For processing images of ice-embedded PDE6, 12,970 particles were selected and corrected for the contrast transfer function using Ctfit. The structure was refined using C 1 symmetry and either an initial model generated from reference-free class averages or a cylinder starting model. The two refined models were essentially similar. After multiple rounds of iterative alignment, classification, reconstruction, and refinement, a final C 1 three-dimensional map was generated from a set of 9200 particles and low-pass filtered to 22 Å.
For the PDE6⅐ROS-1-Fab complex, a total of 21,100 particles were picked from ice images and corrected for the contrast transfer function using Ctfit. After an initial three-dimensional model was generated as described for PDE6, three noise-seeded models were generated and used as initial models in the Multirefine procedure. A model with two Ros-1 Fabs bound with a population of ϳ15,000 particles emerged and was subject to further refinement using standard iterative projection matching, class averaging, and Fourier reconstruction. The final three-dimensional maps with C 1 and C 2 symmetry were generated from 12,373 particles. The resolution was determined by splitting data into even and odd halves to generate a "gold standard" Fourier shell correlation (FSC) curve, which indicated a resolution of ϳ18 Å and ϳ17 Å for the C 1 and C 2 models, respectively, at FSC ϭ 0.5 and ϳ11 Å at FSC ϭ 0.143. The PDE6⅐ROS-1-Fab map has been deposited in the EMDataBank with accession code EMD-6258.
PDE6⅐HA-Fab complexes were imaged in ice. For the N-terminally labeled complex, ϳ13,000 particles of PDE6⅐HA-PDE6␥⅐HA-Fab were subjected to multiple iterations of Multirefine using different starting models, as described for the PDE6⅐ROS-1-Fab complex, generating three final models. The particles corresponding to the model with the largest population (ϳ8500 particles) were used to generate an averaged map that was low-pass-filtered at 30 Å resolution. The same procedure was used for the C-terminally labeled complex (PDE6⅐PDE6␥-HA⅐HA-Fab). Starting with ϳ8000 particles, three models were generated with Multirefine, and the ϳ4500 particles corresponding to the most populated conformation were selected and used to generate an averaged map and lowpass-filtered at 30 Å.
For the PDE6⅐PrBP/␦ complex imaged in ice, a total of ϳ4100 particles (with both single and double occupancy of the two PrBP/␦ binding sites) were selected and used for standard refinement procedures in EMAN. A low resolution map (30 Å) of PDE6 generated from ice images was used as the starting model for the iterative refinement procedure. The consistency between projections of the three-dimensional reconstruction and reference-based class averages supports the accuracy of the map. The final three-dimensional map with C 2 symmetry imposed was generated from ϳ3500 particles and low-passfiltered to 30 Å. A low resolution map of negatively stained PDE6 was constructed from about 1000 particles, as described above for PDE6⅐PrBP/␦. tPDE6 tilt series alignment and three-dimensional tomographic reconstruction were performed with IMOD software (36) . For standard single-particle analysis of tPDE6, 4100 negatively stained particles were picked from 45 micrographs (inclined from ϩ40.26°to Ϫ47.82°) and subjected to Multirefine based on three starting models with C 2 symmetry imposed. The resulting three subgroups contained 1450, 1370, and 1280 particles, and the final models were low-pass-filtered at 30 Å after a single iterative refinement with C 2 symmetry. Similar models were obtained from an independent data set of 15,560 negatively stained particles imaged without tilt (not shown). For single-particle tomography, 120 sub-volumes were averaged with or without C 2 symmetry imposed.
Fitting of GAFa, GAFb, and Fab x-ray structures into the PDE6⅐ROS-1-Fab map was performed using UCSF Chimera (37) . Fitting results for GAFb and Fab structures were confirmed with Foldhunter (38) . Fitting of the PDE catalytic domain was done manually, with constraints as described under "Results." Fitting of PrBP/␦ and Fab in low resolution maps was done manually. Molecular graphics were rendered using Chimera (37) and PyMOL (Schrödinger).
RESULTS
Low Resolution Structure of PDE6 in Vitreous Ice-A typical field of PDE6 molecules suspended in vitreous ice is shown in Fig. 1A . Despite the much lower image contrast obtained in ice, bell-like "front" views resembling those previously observed in negative stain (12) (13) (14) could clearly be seen as well as less featurerich views representing side or top/bottom orientations. A final map was generated from ϳ9200 particles (Fig. 1C) , and comparison of class averages and corresponding model projections (Fig.  1B) indicates good agreement of the model with the data.
The overall appearance of the map is similar to that of previously reported models of PDE6 imaged in negative stain (12) (13) (14) , exhibiting a flattened and extended shape with two prominent cavities. Most of the structure has an approximate 2-fold symmetry as a consequence of the 84% sequence similarity between the PDE6␣ and PDE6␤ subunits. There is a clear asymmetry in the top portion, which has previously been attributed to the N terminus of PDE6␣/␤ (13) , where the homology between PDE␣ and PDE6␤ is low, with 31% identity in the first 90 amino acids compared with 74% overall.
Improved Resolution Using PDE6⅐ROS-1-Fab Complexes and 2-Fold Symmetry-To provide greater mass and additional features to improve alignment, PDE6 was imaged in complex with the ROS-1 Fab (Fig. 2) . Compared with PDE6 alone, front and top/bottom views of PDE6⅐ROS-1-Fab complexes contain clearly visible extra density on two sides ( Fig. 2A) . A threedimensional reconstruction was generated from 12,373 particles in vitreous ice (Fig. 2 ). The overall shape of the PDE6⅐ROS-1-Fab three-dimensional structure is similar to that of PDE6 alone, with the addition of extra density protruding from the bottom in approximately 2-fold symmetrical positions (Fig.  3A) . This extra density is well fit by a Fab molecule (Fig. 3B ), providing unambiguous assignment as the ROS-1-Fab and localization of the ROS-1 binding site. This antibody has high affinity for the holo-PDE6 complex, PDE6␣␤␥␥, but low affinity for either PDE6␥ or PDE6␣␤, and its binding inhibits activation of PDE6 by trypsin, histone 2B, or activated G protein (29, 39 -41) . 4 These observations suggest that ROS-1 specifically recognizes the complex of PDE6␥ with the catalytic subunits and likely binds at the interface between them. The 2-fold symmetry indicates that the two ROS-1 binding sites are likely composed of structurally similar sites on PDE6␣/␥ and PDE6␤/␥, and the catalytic domains are related to one another in an approximately symmetric way.
To further improve the resolution, C 2 symmetry was imposed during the reconstruction, yielding a final map with resolution of ϳ17 Å by the conservative 0.5 FSC criterion and ϳ11 Å by the alternative criterion of 0.143 FSC (42) (Fig. 2E ). The overall shape of the C 1 and C 2 maps are similar (Fig. 2, B and C) . Although asymmetric features such as the PDE6␣/␤ N terminus are averaged out by symmetry imposition, other structures of the GAF and catalytic domains are more clearly revealed.
The greatly improved resolution of this structure compared with that of PDE6 alone is highlighted by the clear visualization of ␣ helices in the catalytic subunits and the cavity between the constant and variable domains of the Fab, which is Ͻ5 Å wide. The new structure reveals a long dimer interface between the GAF domains of PDE6␣ and PDE6␤, similar to that of PDE2A (11) (PDB ID 3IBJ) ( Figs. 2 and 4) . The entire PDE2A GAF domains fit reasonably well in the PDE6 map (Fig. 4A) , although the fit is improved by permitting independent orientation of the GAFa and GAFb domains (Fig. 4B) . The difference in relative orientations between the GAF domains in PDE2A and PDE6 is highlighted in Fig. 6 . These results are contrary to previously published PDE6 GAF domain orientations based on a low res-olution map (14) , but in good agreement with a recently published model of PDE6 (64) . The location of the non-catalytic cGMP binding site, inferred from the fitting of the cone PDE6C GAFa/cGMP crystal structure (9) (PDB ID 3DBA), is shown in Fig. 4C .
The catalytic domain contains fewer features to guide the fitting, and the orientation is therefore subject to more uncertainty. Nevertheless, when constrained so that the N-terminal residues of the catalytic domain (yellow spheres, Fig. 5, A and B) are close to the GAFb domain, as needed for continuity, a satisfactory fit was obtained. The most C-terminal residues (red spheres, Fig. 5, A and B) , which lead to the membrane-binding C-terminal isoprenylated peptides, are positioned near the base of the structure. Fitting the PDE5/6 chimeric catalytic domain crystal structure (PDB ID 3JWR), which contains 17 residues of PDE6␥ (10), in this orientation places the PDE6␥ C terminus near the ROS-1 binding site (Fig. 5, A and B) , consistent with the ␥-subunit-dependent binding of the ROS-1 mAb (29) . Alignment with the PDE5A catalytic domain/GMP structure (8) (PDB ID 1T9S) (Fig. 5, C and D) shows the active site with bound product, GMP (cyan), facing away from the GAF domains and toward the base, facing solvent at the enzyme surface. The difference in relative orientation of the catalytic domains in PDE6 and PDE2A is shown in Fig. 6 . Although this striking difference in arrangements is surprising, given the nearly identical folds of the PDE6 and PDE2 catalytic domains, MAY 15, 2015 • VOLUME 290 • NUMBER 20
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it is supported by a recently published comprehensive model of PDE6 constrained by cross-linking and mass spectrometry (64) .
PDE6⅐PrBP/␦ Structure-PrBP/␦ is a 17.5-kDa protein that binds to the farnesyl and geranylgeranyl modifications at the C terminus of PDE6␣ and PDE6␤, respectively (43) (44) (45) . To obtain a structure of PrBP/␦-bound PDE6, complexes were imaged in vitreous ice. Visual inspection of micrographs revealed a heterogeneous mixture of particles that appeared to contain 0 (ϳ35%), 1 (ϳ40%), or 2 (ϳ25%) bound PrBP/␦ molecules. Examples of single particles with one or two bound PrBP/␦ are shown in Fig. 7A, i and ii, respectively. 3523 particles with either single or double occupancy of the PrBP/␦ binding sites were used for reconstruction with C 2 symmetry imposed ( Fig. 7, B and C) . The structure is similar to the low resolution map of PDE6, with extra mass near the base, consistent with previous evidence from projection maps (14) . The crystal structure of PrBP/␦ (46) fits well into the extra mass. The PrBP/␦ binding site is in good agreement with the modeled locations of the PDE6␣/␤ C termini (compare Figs. 5 and 7C) , further supporting our fitting of the catalytic domain.
Disposition of PDE6␥ Subunits-To identify the locations of the N and C termini of PDE6␥, PDE6 with the ␥ subunit removed by limited trypsin digestion (tPDE6) was reconstituted with recombinant PDE6␥ tagged with HA epitopes at the N or C terminus. Complexes with a Fab fragment from a monoclonal antibody specific for the HA epitope were imaged (Fig.  8A) . Significant heterogeneity was observed, particularly with the N-terminal tag, presumably either because of the flexible linker between the HA tag and PDE␥ or because the N terminus is not always associated with PDE6␣␤. The reconstructions shown represent the majority populations. The results reveal added mass of the correct size and shape for an Fab fragment at the "top" of the structure, i.e. near the GAFa domain, for the N-terminal epitope tag, and near the catalytic domain for the C-terminal tag, consistent with previous cross-linking results (20, 27, 64) . The distance between the two HA-Fab binding sites is ϳ90 Å (Fig. 8B) .
Effect of PDE6␥ on PDE6 Structure-Removal of PDE6␥ by limited trypsin digestion had a dramatic effect on PDE6 structure (Fig. 9 ). The bell-like particles characteristic of PDE6 front views were largely absent, with most particles (ϳ80%) appearing donut-like in projection (Fig. 9A) . Removal of PDE6␥ also introduced significant conformational heterogeneity. Using the EMAN (35) Multirefine routine with three starting models yielded three similarly populated conformations (Fig. 9D) , potentially representing a range of dynamically interchangeable conformations that may well include more than three different states. To further confirm the structural rearrangement of tPDE6, an independent map was constructed by single particle tomography (47, 48) using 120 sub-volumes from tomograms of negatively stained samples (Fig. 9E) . The overall features of the models generated from standard single particle procedures and single-particle tomography are similar.
In addition to removal of PDE6␥, trypsin treatment also results in cleavage of the catalytic subunits near the C terminus (49) . However, the structural rearrangement was reversed upon reconstitution of tPDE6 with recombinant PDE6␥ (Fig. 9B) , confirming that it is in fact the PDE6␥ polypeptide that is essential for conformational stability of PDE6.
DISCUSSION
Imaging of PDE6⅐ROS-1-Fab complexes in ice has provided greater structural detail than previously available, permitting fitting of all three catalytic subunit domains with reasonable confidence (see Figs. 2-6 ). The resulting orientation of domains is significantly different from that reported previously (14) . The most striking feature of the new higher resolution map is the long dimer interface, which was not discernible in low resolution structures (12) (13) (14) . Whereas the overall domain organizations of PDE6␣␤ and PDE2A are similar, the relative positions of the domains are different (see Fig. 6 ). Although (11)) and PDE6⅐ROS-1-Fab structures. Left, the PDE6 C 2 model shown with fitting of the intact PDE2A GAF domains (purple). Right, x-ray structure of PDE2A at 11 Å with GAF domain sequences also shown as ribbons (purple). B, independent fitting of GAFa domains from chicken cone PDE6C (PDB 3DBA (9)) (orange, blue) and GAFb domains from PDE2A (cyan, green). C, alignment of GAFa domain structures from PDE2A (pink) and PDE6C (orange) crystals, showing the location of the non-catalytic cGMP binding site in PDE6C (blue).
catalytic domains are conserved and structurally similar among PDE family members, their orientation with respect to GAF domains appears to be variable. The catalytic domains of PDE6 and PDE2A are in strikingly different orientations, possibly reflecting the different modes of regulation of the enzymatic activity. In the full-length PDE2A crystal the two catalytic domains are oriented such that the two substrate binding sites (10)) is shown as a pink ribbon, with the N terminus (yellow spheres), C terminus (red spheres), and the PDE6␥-(71-87) peptide (blue) indicated. The Fab structure is as in Fig. 3 . C and D, enlarged view of the catalytic domain, with the crystal structures of the PDE5/6 chimera (pink) and PDE5A/GMP (PDB 1T9S (8)) (yellow) aligned. GMP is shown in cyan. MAY 15, 2015 • VOLUME 290 • NUMBER 20 occlude each other at the dimer interface, and it was proposed that cGMP binding to the GAFb domain causes the catalytic domains to move apart (11) . In contrast, the PDE6 catalytic site is occluded by PDE6␥; sequestration of the PDE6␥ C terminus by G ␣t is required for activation (10, (15) (16) (17) (18) .
Domain Organization and Conformational Plasticity of PDE6
The precise orientation of PDE6 with respect to the membrane is unknown; a proposed model is shown in Fig. 10 . Both the PrBP/␦ binding sites (see Fig. 7 ) and the catalytic domain fitting (see Fig. 5 ) place the membrane-anchoring prenyl chains of PDE6␣ and -␤ near the outer edge of the catalytic domains. This location, far away from the long axis of the catalytic domain region, suggests that PDE6 maintains a relatively upright orientation (Fig. 10, A and B) . The catalytic domain fitting suggests that the catalytic cGMP binding site and the C terminus of PDE6␥ are at the "bottom" face of the molecule (Fig. 10A, see Fig. 5 ). An active site location near the membrane surface fits well with biochemical studies of PDE6 activation by G ␣t ; efficient activation requires that both the activated G ␣t subunit and PDE6 have intact lipidated membrane binding regions and requires a membrane surface on which they interact (50, 51) . Moreover, the nature of the phospholipids forming the surface has a strong effect on the efficiency of activation (50 -55) . However, the fact that PDE6 is easily eluted from ROS membranes in hypotonic conditions (3, 28) indicates that the catalytic domains probably do not make extensive interactions with the lipid bilayer. Rather, the membrane may enhance PDE6 activation by favoring the optimal interaction between PDE6 and G ␣t and/or the correct PDE6 conformational change.
To allow G ␣t access to the PDE6␥ C terminus and exposure of the active site, a change in orientation with respect to the membrane may be necessary. Both PDE6␣ and -␤ have ϳ40 (62)) are shown in purple. B, the distance between the HA epitopes in PDE6 reconstituted with HA-PDE6␥ and PDE6␥-HA was estimated by superimposing the two maps. in the presence of excess recombinant PDE6␥. C, Coomassie-stained gel of PDE6 before and after trypsin treatment and reconstituted with recombinant PDE6␥. D, single particle Multirefine procedure starting with ϳ4100 particles and three initial models yielded three similarly populated subsets of particles. The models (with C 2 symmetry imposed) were low-pass filtered to 30 Å and are shown in three orthogonal views. E, C 1 and C 2 maps constructed by single particle tomography using 120 sub-volumes are shown in the same orientations as in D. F, comparison of PDE6 and tPDE6 maps from samples in negative stain. Three-dimensional maps (with C 2 symmetry) are shown in an isosurface representation with the contour level approximating the PDE6 and tPDE6 molecular mass of 220 and 200 kDa, respectively. The atomic model of PDE6␣␤, as shown in Fig. 6 , is docked into the PDE6 map. The tPDE6 map is shown with a speculative rearrangement of the domains.
additional amino acids C-terminal to the region homologous with the PDE5/6 chimera construct (10) used for fitting. It is therefore possible, despite the location of the prenyl chains in the PDE6⅐PrBP/␦ structure (see Fig. 7 ), that stretching out of one of these C termini could allow the entire enzyme to tilt to one side while still keeping both prenyl chains in the membrane. We also propose an alternative possible mechanism whereby the catalytic domains rotate in opposite directions such that both PDE6␣ and -␤ C termini approach the membrane and the active sites become accessible (Fig. 10C ). PDE6␥ regions that do not interact with G ␣t can potentially stabilize the domain arrangement through contacts with both the catalytic domains and the GAFa domain (20, 27, 56, 64 ) (see Fig. 8 ).
The arrangement of domains is likely to be dynamic. For example, there is a significant difference in the relative orientations of the GAFa and GAFb domains of PDE2A in unliganded and nucleotide-bound states (11, 57) . Dynamic arrangement is also suggested by the severe but reversible reorganization observed upon removal of PDE6␥ by limited trypsin digest (see Fig. 9 ). Although the tPDE6 structure demonstrates the ability of PDE6 to undergo dramatic reversible domain rearrangements, its physiological relevance is unknown. Trypsinization of PDE6 causes degradation and/or dissociation of the entire PDE6␥ peptide (58) . In contrast, when activated by transducin, PDE6␥ is displaced from the active site but may remain bound to the complex (50, 51, 56, 59, 60) . In addition, the C-terminal cleavages of PDE6␣ and -␤ caused by trypsin (49), although not sufficient for the rearrangement, may contribute to structural instability. Regardless, the apparently normal structure of tPDE6 reconstituted with recombinant PDE6␥ supports the use of this model system in structural studies, such as in the HA-Fab labeling experiments.
Our data place the PDE6␥ C terminus at the catalytic domain, as expected, and the N terminus near the GAFa domain (see Fig. 8 ). In addition to its role in inhibiting enzyme activity at the catalytic domain, PDE6␥ also participates in reciprocal regulation of cGMP binding to the non-catalytic sites in the GAF domains. Binding of PDE6␥ enhances the affinity for cGMP at the non-catalytic sites, and binding of cGMP to the GAF domains in turn increases the affinity of the catalytic domains for PDE6␥ (22) (23) (24) (25) . It has been proposed on the basis of cross-linking, mutagenesis, and genetic studies that the N-terminal region of PDE6␥ binds directly to one or both of the GAFa domains of PDE6␣␤ (20, 27, 61, 64) . Our data provide direct structural evidence supporting this type of interaction for both copies of PDE6␥ in the holoenzyme.
In the crystal structure of a C-terminal fragment of PDE6␥ bound to activated transducin (5), residues 50 -87, comprising almost half of the molecule, assume a compact globular structure in its complex with activated G protein and RGS protein. Biochemical evidence indicates that these proteins and PDE6␣␤ bind PDE6␥ simultaneously (56, 60) , so this compact structure is likely compatible with tight binding to PDE6␣␤. In this scenario, nearly the entire N-terminal half of the molecule must adopt an extended chain conformation to reach from the catalytic base of PDE6 to the GAFa domains. Even if only the structured part of PDE6␥ (residues 76 -87) visible in its complex with the catalytic fragment of the PDE5/6 chimera (10) is globular in the native heterotetramer, the remainder of PDE6␥ would still have to adopt a largely extended conformation to reach the GAFa domain.
The results presented here allow the wealth of biochemical data about PDE6 and the related PDE5 isozymes to be placed in the context of a three-dimensional structure. The structural models presented pose many hypotheses about structure-function relationships that can now be addressed by combining biochemical and mutagenesis studies with further cryo-EM studies using site-specific labels.
